You are here

FDA Issues Risk Alert About Bulk Drug Substance Cesium Chloride

Part of an ongoing effort to better oversee use of compounded medications.

In its continuing effort to ensure the safety and efficacy of compounded medications, the FDA yesterday issued a compounding risk alert about cesium chloride, which is sometimes used by cancer patients. The alert, issued to providers and patients, states that “serious adverse events associated with the use of cesium chloride and other cesium salts include abnormal heart rhythms (arrhythmias), low potassium (hypokalemia), seizures, fainting (syncope), cardiac arrest and death.”

Recent Headlines

Citrus, Berries, Broccoli Reduce Risk of Cancer and CVD
Changes in Antibiotic Recommendations for Children
Influences Gene Involved in Circadian Rhythms
‘The Perfect Drug for Trauma-Focused Psychotherapy’
Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients